| 10/7/2024 | SP | New Issue: BMO sells $3.29 million contingent market-linked autocalls on stocks
|
| 8/22/2024 | SP | New Issue: JPMorgan prices $1.43 million return notes linked to basket of 20 stocks
|
| 5/23/2024 | SP | New Issue: HSBC prices $1.8 million contingent income barrier autocalls with memory on two stocks
|
| 5/15/2024 | SP | New Issue: GS Finance prices $5.01 million autocallable basket-linked notes on stock basket
|
| 1/29/2024 | BK | Abbott Laboratories enters into $5 billion five-year revolving facility
|
| 12/12/2023 | SP | New Issue: RBC prices $587,000 notes linked to 35 Raymond James securities selections
|
| 10/18/2023 | SP | New Issue: JPMorgan prices $1.58 million autocallable contingent interest notes on two stocks
|
| 10/16/2023 | SP | New Issue: JPMorgan sells $2.35 million autocallable contingent interest notes on three stocks
|
| 10/8/2023 | SP | New Issue: HSBC prices $774,000 17.5% contingent income barrier autocalls on stocks
|
| 9/19/2023 | SP | New Issue: RBC prices $1.45 million levered market plus notes linked to stock basket
|
| 6/28/2023 | SP | New Issue: JPMorgan prices $1.58 million return notes linked to basket of 20 stocks
|
| 6/12/2023 | BKIG | Moody's lifts Abbott Laboratories
|
| 5/30/2023 | SP | New Issue: Citigroup prices $750,000 9% securities linked to Truist, Abbott, Union Pacific
|
| 2/22/2023 | SP | New Issue: HSBC prices $500,000 autocallable contingent income barrier notes on three stocks
|
| 12/21/2022 | SP | New Issue: JPMorgan sells $2.68 million trigger autocallable contingent yield notes on Abbott
|
| 11/18/2022 | SP | New Issue: GS Finance prices $1.93 million autocallable contingent coupon equity notes on Abbott
|
| 11/1/2022 | SP | New Issue: JPMorgan prices $241,000 autocallable contingent interest notes on pharma stocks
|
| 10/4/2022 | SP | New Issue: HSBC sells $500,000 autocallable contingent income barrier notes with memory on stocks
|
| 10/3/2022 | SP | New Issue: UBS prices $1.97 million trigger autocallable contingent yield notes on Abbott
|
| 8/26/2022 | SP | New Issue: JPMorgan prices $650,000 12.15% autocallable contingent interest notes on three stocks
|
| 6/25/2022 | SP | New Issue: CIBC sells $1.19 million contingent coupon autocallable barrier notes on three stocks
|
| 4/27/2022 | SP | Market Commentary: Citi reintroduces older structure with $6.66 million variable coupon notes on 10-stock basket
|
| 4/22/2022 | SP | New Issue: Citigroup prices $6.66 million variable coupon market-linked notes on 10-stock basket
|
| 4/4/2022 | SP | New Issue: Credit Suisse sells $600,000 contingent coupon reverse convertibles on three stocks
|
| 4/1/2022 | SP | New Issue: UBS prices $2.23 million trigger autocallable contingent yield notes on Abbott Laboratories
|
| 3/9/2022 | BKIG | S&P lifts Abbott Laboratories
|
| 2/15/2022 | BKIG | Moody's boosts Abbott Labs
|
| 12/23/2021 | SP | New Issue: RBC sells $1.22 million trigger autocallable contingent yield notes on Abbott
|
| 8/10/2021 | SP | New Issue: UBS sells $894,000 trigger autocallable contingent yield notes add-on on pharma stocks
|
| 6/9/2021 | SP | New Issue: UBS prices $3 million trigger autocallable contingent yield notes on pharma stocks
|
| 5/20/2021 | BKIG | Moody's upgrades Abbott
|
| 5/19/2021 | BKIG | S&P raises Abbott Labs
|
| 11/12/2020 | BK | Abbott Laboratories enters $5 billion five-year revolving facility
|
| 11/11/2020 | SP | New Issue: TD Bank prices $285,000 autocallable contingent interest barrier notes on Abbott
|
| 11/10/2020 | BKIG | S&P raises Abbott Labs
|
| 10/28/2020 | SP | New Issue: UBS prices $1.37 million trigger autocallable contingent yield notes on Abbott Laboratories
|
| 9/28/2020 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Abbott Labs
|
| 9/23/2020 | SP | New Issue: RBC prices $655,000 notes on basket of 25 Raymond James stock picks
|
| 9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
| 6/26/2020 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Abbott
|
| 6/23/2020 | IG | Market Commentary: AerCap, CNH, Arch, Niagara Mohawk, UniCredit in primary; credit spreads firm
|
| 6/23/2020 | IG | Market Commentary: Morning Commentary: Niagara Mohawk, CNH, Teck, AerCap, Arch offer bonds; issues mixed
|
| 6/22/2020 | EMHYPFPV | Market Commentary: Abbott, Canadian Resources, Duke Realty price; Arch Capital on tap
|
| 6/22/2020 | IG | Market Commentary: Abbott, Canadian Resources, Duke Realty price; Arch Capital on tap; credit spreads improve
|
| 6/22/2020 | IG | New Issue: Abbott Labs prices $1.3 billion of fixed-rate notes in two parts
|
| 6/22/2020 | SP | New Issue: UBS prices $175,000 trigger phoenix autocallables linked to Abbott
|
| 6/22/2020 | BKIG | Moody’s assigns Abbott notes A3
|
| 6/22/2020 | IG | Market Commentary: Morning Commentary: Abbott, Canadian Natural Resources, Arch Capital notes on deck
|
| 6/22/2020 | BKIG | S&P rates Abbott notes A-
|
| 6/22/2020 | IG | Abbott Laboratories intends to sell fixed-rate notes in two tranches
|
| 6/11/2020 | SP | New Issue: JPMorgan sells $1.2 million contingent interest autocalls on two stocks
|
| 5/8/2020 | SP | New Issue: GS Finance prices $4.05 million capped trigger securities on basket of 20 stocks
|
| 4/27/2020 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Abbott
|
| 4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
| 4/15/2020 | SP | New Issue: UBS prices $1.93 million trigger autocallable contingent yield notes on Abbot
|
| 2/13/2020 | SP | New Issue: JPMorgan sells $2.96 million trigger autocallable contingent yield notes on Abbott Laboratories
|
| 12/19/2019 | IGLM | Abbott redeems all $2.85 billion 2.9% notes due 2021 at 101.972
|
| 11/5/2019 | BKIG | S&P ups Abbott Labs
|
| 8/27/2019 | SP | New Issue: CIBC prices $390,000 notes linked to 30 stocks picked by Raymond James
|
| 5/3/2019 | BKIG | Moody’s lifts Abbott ratings
|
| 4/17/2019 | BKBWIG | Abbott Labs repays $10 billion of debt since 2017; more to be repaid
|
| 3/18/2019 | BKIG | S&P elevates Abbott Labs
|
| 1/31/2019 | SP | New Issue: JPMorgan prices $1.4 million 8% contingent yield trigger autocalls tied to Abbott
|
| 1/16/2019 | SP | JPMorgan eyes trigger autocallable contingent yield notes on Abbott
|
| 12/24/2018 | SP | New Issue: UBS sells $631,000 trigger autocallable contingent yield notes on Abbott
|
| 11/30/2018 | BK | Abbott Laboratories secures $5 billion five-year revolving facility
|
| 10/29/2018 | IGLM | Abbott Laboratories, St. Jude unit redeem $4 billion of senior notes
|
| 10/26/2018 | SP | New Issue: JPMorgan prices $1.33 million 9.5% contingent interest autocalls on two stocks
|
| 9/14/2018 | BKIG | Moody’s rates Abbott Lab notes Baa1
|
| 9/14/2018 | BKIG | S&P gives Abbott Lab notes BBB
|
| 8/28/2018 | BKIG | Moody’s ups Abbott Labs debt
|
| 7/26/2018 | SP | New Issue: RBC prices $2 million 8.05% contingent coupon autocalls on three stocks
|
| 6/22/2018 | IGLM | Abbott redeems $1.3 billion portion of 2.35% notes due 2019
|
| 6/11/2018 | BKIG | S&P lifts Abbott Labs view to positive
|
| 4/2/2018 | SP | New Issue: CIBC sells $495,000 notes on eight Raymond James top pick healthcare stocks
|
| 4/2/2018 | SP | New Issue: CIBC sells $285,000 Raymond James Healthcare Top Selections notes on 16 stocks
|
| 4/2/2018 | SP | New Issue: CIBC sells $548,000 notes on eight Raymond James top pick healthcare stocks
|
| 3/22/2018 | IGLM | Abbott redeems all 5.125% notes due 2019, some 2.35% notes due 2019
|
| 3/20/2018 | SP | CIBC plans notes on eight Raymond James top pick healthcare stocks
|
| 3/20/2018 | SP | CIBC to price notes on eight Raymond James top pick healthcare stocks
|
| 3/20/2018 | SP | CIBC plans Raymond James Healthcare Top Selections notes on 16 stocks
|
| 3/20/2018 | SP | CIBC to price notes on 16 Raymond James top pick healthcare stocks
|
| 2/13/2018 | BKIG | Moody's upgrades Abbott
|
| 2/12/2018 | BKCVIG | Moody’s ups Abbott Laboratories
|
| 11/6/2017 | EMIGLM | CFR International calls 5.125% notes due 2022 for redemption
|
| 10/4/2017 | CVLM | Abbott buys 98.5% of Alere’s convertible preferreds in tender offer
|
| 10/2/2017 | CVLM | Abbott once more extends tender for Alere’s convertible preferreds
|
| 9/18/2017 | CVLM | Abbott again extends tender for Alere’s convertible preferreds
|
| 9/1/2017 | CVLM | Abbott further extends tender for Alere’s convertible preferreds
|
| 8/28/2017 | HYLM | Alere calls 6 3/8% notes due 2023 on closing of acquisition by Abbott
|
| 8/14/2017 | CVLM | Abbott extends tenders for Alere’s convertible perpetual preferreds
|
| 7/31/2017 | BK | Abbott enters $2.8 billion term loan agreement for Alere acquisition
|
| 7/17/2017 | CVLM | Abbott tenders for Alere’s series B convertible perpetual preferreds
|
| 3/23/2017 | IGLM | Abbott swaps out all but $194.25 million of five St. Jude note series
|
| 3/7/2017 | IGLM | Abbott takes in tenders of 90%-plus of each series of St. Jude notes
|
| 2/28/2017 | BKCVIG | Fitch gives BBB to Abbott notes
|
| 2/23/2017 | BKCVIG | Moody’s rates Abbott notes Baa3
|
| 2/21/2017 | IGLM | Abbott starts exchange offer, consent solicitation for St. Jude notes
|
| 1/5/2017 | BKCVIG | Moody’s drops Abbott, rates St. Jude loans Baa3
|
| 1/5/2017 | BKCVIG | Fitch lowers Abbott, St. Jude
|
| 1/4/2017 | BKIG | S&P downgrades Abbott
|
| 12/30/2016 | IG | Market Commentary: Outlook 2017: High-grade supply to stay robust; bond views mixed; mergers remain on forefront
|
| 12/23/2016 | SP | New Issue: Barclays prices $8 million 6.5% airbag autocallable yield notes linked to Abbott
|
| 12/16/2016 | BK | Abbott Laboratories enters $2 billion 120-day bridge loan agreement
|
| 12/16/2016 | SP | Barclays to price 6.25%-7% airbag autocallables linked to Abbott
|
| 11/23/2016 | IG | Market Commentary: Morning Commentary: High-grade primary action thins; Bank of America, Abbott mostly unchanged
|
| 11/22/2016 | EMHYPFPV | Market Commentary: KfW prices upsized $1.5 billion green notes; Duke Energy, Time Warner firm; Abbott eases
|
| 11/22/2016 | IG | Market Commentary: KfW prices upsized $1.5 billion green notes; Duke Energy, Time Warner notes firm; Abbott eases
|
| 11/22/2016 | IG | Market Commentary: Morning Commentary: Pre-holiday investment-grade primary activity slows; Abbott bonds mixed
|
| 11/21/2016 | EMHYPFPV | Market Commentary: Bank of America, BP Capital, Enbridge among issuers; credit spreads firm; Abbott tightens
|
| 11/21/2016 | IG | Market Commentary: Bank of America, BP Capital, Enbridge among issuers; credit spreads firm; Abbott tightens
|
| 11/21/2016 | IG | Market Commentary: Morning Commentary: Enbridge, Bank of America prep deals; bonds mixed; Abbott Labs better
|
| 11/18/2016 | EMHYPFPV | Market Commentary: Light volume seen for holiday week; Abbott, Pfizer mixed; Chevron Phillips Chemical firms
|
| 11/18/2016 | IG | Market Commentary: Light volume forecast for holiday week; Abbott, Pfizer mixed; Chevron Phillips Chemical firms
|
| 11/18/2016 | IG | Fitch assigns A to Abbott notes
|
| 11/18/2016 | IG | New Issue: Abbott Labs details $15.1 billion six-tranche sale of fixed-rate notes
|
| 11/17/2016 | EMHYPFPV | Market Commentary: Abbott Labs sells $15.1 billion notes; KeyBank, Chevron Phillips Chemical tap market
|
| 11/17/2016 | IG | Market Commentary: Abbott Labs sells $15.1 billion notes; KeyBank, Chevron Phillips Chemical tap market
|
| 11/17/2016 | IG | New Issue: Abbott Laboratories sells $15.1 billion fixed-rate notes in six parts
|
| 11/17/2016 | BKIG | S&P rates Abbott notes A+
|
| 11/17/2016 | IG | Moody’s rates Abbott Laboratories notes Baa3
|
| 11/17/2016 | IG | Market Commentary: Morning Commentary: Abbott Labs preps six-part deal; HollyFrontier tightens; Westpac Banking flat
|
| 11/17/2016 | IG | Abbott Laboratories intends to sell fixed-rate notes in six tranches
|
| 5/27/2016 | SP | New Issue: RBC prices $1.56 million trigger phoenix autocallables on two stocks
|
| 4/28/2016 | BKIG | Abbott to use new debt to help fund $25 billion St. Jude acquisition
|
| 2/2/2016 | IG | Fitch might lower Abbott
|
| 2/1/2016 | IG | S&P reviews Abbott Laboratories
|
| 2/1/2016 | IG | Moody’s reviews Abbott Laboratories
|
| 2/1/2016 | BKBWHYIGLM | Abbott to use debt to buy Alere, will assume or refinance Alere debt
|
| 12/9/2015 | SP | New Issue: RBC prices $7.39 million autocallable reverse convertibles linked to three stocks
|
| 5/18/2015 | IG | Fitch cuts Abbott Laboratories IDR to A
|
| 3/5/2015 | EMHYMUPFPV | Market Commentary: Energy Transfer, Abbott, John Deere price; supply tops $60 billion; Coach, Microsoft firm
|
| 3/5/2015 | IG | Market Commentary: Energy Transfer, Abbott, John Deere price; supply tops $60 billion; Coach, Microsoft firm
|
| 3/5/2015 | IG | New Issue: Abbott Laboratories prices $2.5 billion of notes in three maturities
|
| 3/5/2015 | IG | Moody’s lowers Teck to Baa3
|
| 3/5/2015 | IG | Moody’s lowers Teck to Baa3
|
| 3/5/2015 | IG | Moody’s rates Abbott Labs notes A2
|
| 3/5/2015 | IG | S&P rates Abbott notes A+
|
| 3/5/2015 | IG | Abbott Laboratories talks three-part notes offer for Thursday pricing
|
| 3/4/2015 | IG | Moody’s drops Abbott Laboratories debt to A2
|
| 1/15/2015 | EMIGLM | Abbott receives tenders for $1.2 million more of CFR’s 5.125% notes
|
| 12/30/2014 | EMIGLM | Abbott receives tenders for 97.6% of CFR’s $300 million 5.125% notes
|
| 12/15/2014 | EMIGLM | Abbott tenders for CFR unit’s $300 million 5.125% senior notes due 2022
|
| 7/15/2014 | IG | Moody's: Abbott's unchanged
|
| 5/20/2014 | EM | S&P: CFR Pharmaceuticals on positive watch
|
| 5/20/2014 | IG | Fitch drops Abbott to negative
|
| 5/19/2014 | HY | Fitch might lift CFR Pharmaceuticals
|
| 10/16/2013 | IG | Moody's: Abbott view to negative
|
| 12/31/2012 | IGLM | Abbott Laboratories calls $244.5 million of 5.125% notes due 2019
|
| 12/7/2012 | IGLM | Abbott announces prices for $2.78 billion redemption of notes series
|
| 11/16/2012 | IGLM | Abbott to redeem $2.77 billion of outstanding notes from four series
|
| 11/13/2012 | IGLM | Abbott Laboratories tallies tenders in offer for four series of notes
|
| 11/9/2012 | IGLM | Abbott extends tender offer for four note series, gives early results
|
| 11/8/2012 | IGLM | Abbott Laboratories prices tender offer for nine series of notes
|
| 10/26/2012 | IGLM | Abbott Laboratories launches tender offer for nine series of notes
|
| 10/26/2012 | IG | S&P lowers Abbott
|
| 10/25/2012 | IG | Moody's lifts Abbott to stable
|
| 6/13/2012 | IG | S&P: Abbott on negative watch
|
| 5/10/2012 | IG | Moody's: No change to Abbott
|
| 5/7/2012 | IG | Fitch: Abbott on watch
|
| 3/28/2012 | IG | S&P: Abbott remains on watch
|
| 1/23/2012 | LMMU | Puerto Rico industrial authority calls $53.12 million Abbott Lab bonds
|
| 10/19/2011 | IG | S&P places Abbott on watch
|
| 10/19/2011 | IG | Moody's: Abbott view negative
|
| 8/10/2011 | SP | New Issue: UBS prices $99,969 4.46% trigger yield optimization notes on Abbott Laboratories
|
| 8/10/2011 | SP | New Issue: UBS sells $99,969 6.1% trigger yield optimization notes tied to Abbott Laboratories
|
| 5/31/2011 | IG | Moody's: Abbott unchanged
|
| 5/19/2011 | IG | Fitch: Abbott to negative
|
| 9/22/2010 | IG | Moody's confirms Abbott Labs
|
| 5/25/2010 | IG | Fitch affirms Abbott
|
| 5/25/2010 | IG | Market Commentary: Volatility leaves new bonds absent; industrials move out; Abbott bonds mixed in secondary
|
| 5/24/2010 | IG | New Issue: Abbott Laboratories sells $3 billion of senior notes in five-, 10-, 30-year tranches
|
| 5/24/2010 | IG | S&P rates Abbott notes AA
|
| 5/24/2010 | IG | Moody's gives Abbott notes A1
|
| 5/24/2010 | IG | Market Commentary: Abbott Labs, Georgia Power, Empire District Electric price bonds; Treasuries tighten up
|
| 5/21/2010 | IG | Moody's might downgrade Abbott
|
| 5/21/2010 | IG | S&P affirms Abbott
|
| 9/28/2009 | IG | Moody's cuts Abbott outlook to negative
|
| 9/28/2009 | IG | Fitch affirms Abbott
|
| 9/18/2009 | IG | Market Commentary: National Life Insurance, Zions Bank price bonds; Citigroup, Barclays, Markel trade tighter
|
| 2/27/2009 | CV | Abbott says holders may put three series of Advanced Medical Optics convertibles
|
| 2/27/2009 | IG | Market Commentary: Citigroup, other bank names in focus as day lacks new deals; Citi, GE Capital gain, Chevron better
|
| 2/26/2009 | IG | Fitch rates Abbott notes A+
|
| 2/26/2009 | IG | Market Commentary: Chevron, Danaher, Abbott Labs, Oneok, Alabama Power sell bonds; secondary focuses on recently priced deals
|
| 2/26/2009 | SS | Abbott completes $2.8 billion acquisition of Advanced Medical Optics
|
| 2/26/2009 | IG | New Issue: Abbott Laboratories sells $3 billion 10-, 30-year senior notes
|
| 2/26/2009 | IG | S&P rates Abbott notes AA
|
| 2/26/2009 | IG | Moody's rates Abbott notes A1
|
| 2/25/2009 | SS | Abbott completes tender offer for Advanced Medical Optics
|
| 2/20/2009 | SS | Abbott obtains additional clearance in planned merger with Advanced Medical Optics
|
| 2/12/2009 | IG | Abbott files automatic shelf registration for debt securities
|
| 2/9/2009 | SS | Advanced Medical Optics investor Gamco denies being 'acquiring person'
|
| 2/6/2009 | SS | Abbott's acquisition of Advanced Medical Optics clears waiting period hurdle
|
| 2/6/2009 | SS | Market Commentary: Icahn's move on Biogen seen as sale prep; Abbott buyout on track; TD Ameritrade shares up on new stake
|
| 1/26/2009 | SS | Abbott begins tender offer for Advanced Medical Optics
|
| 1/20/2009 | IG | Market Commentary: Puget Sound Energy, PSEG sell bonds; market conditions, inauguration distract; financials hurt in trading
|
| 1/16/2009 | IG | Fitch affirms Abbott
|
| 1/14/2009 | SS | Advanced Medical Optics shareholder ValueAct agrees to support merger with Abbott
|
| 1/14/2009 | SS | Market Commentary: No Yahoo, Microsoft deal seen ahead; Sierra tender for Wavecom gets regulatory OK, likely to close
|
| 1/12/2009 | SS | Abbott Labs to acquire Advanced Medical Optics in $22-per-share cash tender offer
|
| 1/12/2009 | SS | Market Commentary: Advanced Medical grabs high bid; Aladdin buyout set at $11.50 a share; Landry's falls after deal tanks
|
| 1/12/2009 | IG | S&P affirms Abbott
|
| 1/12/2009 | IG | Moody's affirms Abbott
|
| 10/14/2008 | IG | S&P affirms Abbott
|
| 10/14/2008 | SS | Market Commentary: Teck Cominco drops after stock shuffle; National City sale whispers; Huntsman scores another win
|
| 8/4/2008 | IG | Fitch lowers Abbott
|
| 5/5/2008 | IG | Moody's ups Abbott outlook to stable
|
| 11/8/2007 | IG | Market Commentary: News Corp. prices $1.25 billion 30-year bonds; upcoming holiday damps activity
|
| 11/6/2007 | IG | Moody's rates Abbott notes A1
|
| 11/6/2007 | IG | Fitch assigns Abbott notes AA-
|
| 11/6/2007 | IG | Market Commentary: Tone improves slightly, brings Abbott, Northern Trust, General Electric to market
|
| 11/6/2007 | IG | New Issue: Abbott Laboratories prices upsized $3.5 billion in three tranches
|
| 11/6/2007 | IG | S&P gives Abbott notes AA
|
| 7/12/2007 | SS | Market Commentary: Alcan shines; Alcoa on the run; Huntsman slides; Lyondell up; Abbott off; ImClone declines
|
| 11/8/2006 | BT | RBC keeps Abbott as a top pick
|
| 11/6/2006 | BT | Fitch puts Abbott on negative watch
|
| 11/6/2006 | BT | Market Commentary: Abbott Labs stock off on Kos Pharmaceuticals acquisition news; VaxGen may lose government contract
|
| 11/6/2006 | BT | S&P affirms Abbott Laboratories
|
| 11/6/2006 | BT | Moody's: Abbott outlook negative
|
| 10/24/2006 | BT | RBC reiterates Abbott at top pick
|
| 10/18/2006 | BT | Abbott a top pick for RBC
|
| 10/5/2006 | BT | Abbott reiterated as a top pick by RBC
|
| 9/13/2006 | BT | Abbott launches next-generation embolic protection system in Europe
|
| 9/12/2006 | BT | Abbott expands vascular operations in Ireland for drug-eluting stent
|
| 9/11/2006 | BT | Innogenetics: Jury finds Abbott willfully infringed patent; court awards $7 million in damages
|
| 9/7/2006 | BT | Abbott files for Humira approvals in United States, Europe
|
| 9/5/2006 | BT | Abbott's Xience V drug-eluting coronary stent superior to Taxus in trial
|
| 9/5/2006 | BT | Innogenetics receives unanimous verdict against Abbott
|
| 9/5/2006 | BT | Abbott a top pick by RBC
|
| 8/30/2006 | BT | Abbott completes enrollment in preventive cardiac-care study
|
| 8/29/2006 | BT | Innogenetics gets early favorable judgment in patent infringement suit
|
| 8/14/2006 | BT | Abbott Vascular enrolls first patient in Xience V drug-eluting stent trial
|
| 7/31/2006 | BT | Abbott's Humira gets FDA approval for active ankylosing spondylitis
|
| 7/26/2006 | BT | Abbott to sell i-STAT BNP test to diagnose congestive heart failure
|
| 7/26/2006 | BT | RBC makes Whistle Stop Tour at AACC
|
| 7/20/2006 | BT | Abbott reiterated as a top pick by RBC
|
| 7/20/2006 | BT | Abbott's UroVysion more effective in diagnosing bladder cancer, study says
|
| 7/19/2006 | BT | Abbott announces FDA clearance of Cell-Dyn Ruby hematology instrument
|
| 7/19/2006 | BT | Abbott second-quarter earnings per share of $0.62 beat guidance, operating earnings down 50.4%
|
| 7/18/2006 | BT | Abbott gets FDA approval for automated blood-screening tests for hepatitis B
|
| 7/10/2006 | BT | Bear Stearns reiterates Abbott at outperform
|
| 7/6/2006 | BT | Abbott, Dharmacon to develop new siRNA-based therapeutics
|
| 7/6/2006 | BT | Elan, Abbott sign licensing deal to use NanoCrystal technology to combine cholesterol drugs
|
| 7/5/2006 | BT | Abbott, AstraZeneca to co-develop combination pill for lipid management
|
| 7/3/2006 | BT | Abbott's new tablet formulation for HIV drug Kaletra approved in Europe
|
| 6/27/2006 | BT | Abbott, Cincinnati Children's Hospital to develop urine-based diagnostic assay for kidney injury, disease
|
| 6/26/2006 | BT | FDA approves Abbott's Humira Pen for arthritis
|
| 6/23/2006 | BT | Abbott: Phase 3 data show Humira offers sustained reduction in symptoms of ankylosing spondylitis
|
| 6/13/2006 | BT | Abbott says FreeStyle Navigator shows frequent, accurate glucose monitoring
|
| 6/12/2006 | BT | Abbott's FreeStyle Navigator Continuous Glucose Monitoring System meets study endpoints
|
| 6/7/2006 | BT | Abbott's Humira approved in Europe for ankylosing spondylitis
|
| 5/22/2006 | BT | Abbott's Humira keeps Crohn's patients in remission, data shows
|
| 5/19/2006 | CV | New Issue: CIBC prices $4 million principal-protected notes linked to 10 stocks
|
| 5/16/2006 | BT | Agreement gives Abbott rights to products using PRoGRP biomarker for lung cancer
|
| 5/10/2006 | BT | New Issue: Abbott sells $4 billion bonds; 3-year at T+48 bps, 5-year at T+60 bps, 10-year at T+76 bps
|
| 5/9/2006 | BT | Fitch rates Abbott notes AA-
|
| 5/9/2006 | BT | Market Commentary: Hollis-Eden loses in advance of first-quarter report; Tercica dives 22% after close; Curis rises 17%
|
| 5/9/2006 | BT | Abbott Labs three-part, $4 billion bond deal launched via ABN Amro, Morgan Stanley, BofA, JPMorgan
|
| 5/8/2006 | BT | Abbott Laboratories to hold investor call Tuesday for $4 billion three-part note offering
|
| 5/8/2006 | BT | S&P gives Abbott Laboratories notes AA
|
| 5/8/2006 | BT | Moody's affirms Abbott
|
| 4/28/2006 | BT | Abbott's Humira gets European recommendation for treatment of arthritis of the spine
|
| 4/28/2006 | BT | Abbott's anti-HIV tablet gets marketing approval recommendation from European Medicines Agency
|
| 4/26/2006 | BT | Market Commentary: Inspire trial launch brings buyers; Avigen players hopeful; Applera units mixed; LifeCell lifted 15%
|
| 4/21/2006 | BT | Abbott revises 2006 EPS guidance to $2.44-$2.50 upon closing of Guidant vascular business acquisition
|
| 4/21/2006 | BT | Moody's cuts Abbott Laboratories outlook to negative
|
| 4/19/2006 | BT | Abbott says Q1 EPS hits $0.56, predicts $0.59 to $0.61 for Q2
|
| 4/11/2006 | BT | Myriad, Abbott to collaborate on drug discovery
|
| 4/4/2006 | BT | Abbott seeks registration in South Africa of new formula to treat HIV
|
| 3/29/2006 | BT | DexCom, Abbott patent lawsuit gets new review by trademark office
|
| 3/13/2006 | BT | Abbott gets FDA 510(k) clearance to market glucose test FreeStyle Freedom
|
| 3/3/2006 | BT | Moody's affirms Abbott
|
| 2/28/2006 | BT | Abbott Laboratories files debt shelf
|
| 2/27/2006 | BT | Analyst updates cardiology market from East Coast session
|
| 2/15/2006 | BT | Celera says Abbott has selected two additional cancer targets for development
|
| 2/6/2006 | BT | Abbott selects two of Celera's cancer targets for development
|
| 1/25/2006 | BT | Abbott receives FDA approval to market handheld blood analyzer
|
| 1/19/2006 | BT | Moody's may affirm, lower view on Abbott
|
| 1/17/2006 | BT | S&P's Abbott ratings unaffected
|
| 1/10/2006 | BT | Dade Behring grants sublicense to Abbott for use of PlGF in diagnosis of cardiovascular diseases
|
| 1/9/2006 | BT | Fitch's Abbott ratings unaffected
|
| 1/9/2006 | BT | Boston Scientific adds twist to $25 billion Guidant offer - selling vascular business to Abbott for $3.8 billion
|
| 1/9/2006 | BT | Moody's likely to affirm Abbott
|
| 1/9/2006 | BT | S&P affirms Abbott
|
| 12/22/2005 | BT | Abbott gets FDA OK to market StarClose vascular closure system
|
| 12/22/2005 | BT | Fitch affirms Abbott Laboratories
|
| 12/7/2005 | BT | FDA approves Abbott's Depakote extended release formula for bipolar disorder
|
| 11/30/2005 | BT | Abbott subsidiaries get $1.9 billion in credit facilities
|
| 11/22/2005 | BT | Abbott, Myriad extend alliance to further research on human genetic variation around drug targets
|
| 11/18/2005 | BT | Abbott's Kaletra effectively suppresses HIV viral load in seven-year study
|
| 11/16/2005 | BT | Abbott heart drug levosimendan fails to produce statistically significant reduction in mortality
|
| 11/14/2005 | BT | Abbott phase 3 study shows efficacy of Humira in treating ankylosing spondylitis
|
| 11/14/2005 | BT | Abbott study shows majority of arthritis patients respond to Humira
|
| 11/14/2005 | BT | Abbott's levosimendan boosts standard care for heart failure patients
|
| 11/11/2005 | BT | Court grants Abbott injunction against Andrx's generic version of Biaxin pending full trial
|
| 10/31/2005 | BT | Abbott's new Kaletra formulation for patient convenience approved by FDA
|
| 10/31/2005 | BT | Abbott says Humira study shows "promising" results in Crohn's disease
|
| 10/26/2005 | BT | Cambridge Antibody Technology and Abbott reach royalties settlement
|
| 10/14/2005 | BT | Abbott Laboratories gets FDA not-approvable letter for Xinlay drug application
|
| 9/26/2005 | BT | Abbott Labs price target cut by Bear Stearns
|
| 9/20/2005 | BT | Abbott Labs reiterated by Bear Stearns at outperform
|
| 9/14/2005 | BT | Abbott reiterated by Bear Stearns at outperform
|
| 7/28/2003 | CV | New Issue: Goldman Sachs prices $15 million 5.5% notes exchangeable for Abbott
|
| 7/26/2002 | CV | New Issue: Goldman Sachs prices $22.5 million 7% notes mandatorily exchangeable for Abbott
|
